Payment overview · 2025
General Payments
$8,482.23
74 reported records · 33 companies
Healthcare provider profile · identity verified
John Waples, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology · HUNTSVILLE, AL · NPI 1790765337
Verified facts
What the public records show
CMS Open Payments records show John Waples, M.D. received $8,482.23 in general payments during 2025 across 74 reported records.
KYOWA KIRIN, INC. accounted for 46.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 50 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Brukinsa, Ibrance, Imbruvica, Jakafi, Orgovyx, Somatuline Depot, Xtandi.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 15599 records involving 6881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Imbruvica by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 54 records involving 52 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Ibrance by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORGOVYX as an associated drug or biological on 29 records involving 26 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Orgovyx by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 98 records involving 88 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Xtandi by this doctor in 2024.
BeOne Medicines USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRUKINSA as an associated drug or biological on 10251 records involving 4941 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Brukinsa by this doctor in 2024.
BeiGene USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRUKINSA as an associated drug or biological on 2084 records involving 1673 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Brukinsa by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 318 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SPRYCEL as an associated drug or biological on 32 records involving 32 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Sprycel by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JAKAFI as an associated drug or biological on 14854 records involving 6477 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jakafi by this doctor in 2024.
Ipsen Biopharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Somatuline Depot as an associated drug or biological on 872 records involving 551 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Somatuline Depot by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 47 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Imbruvica by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Xarelto by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LENVIMA as an associated drug or biological on 66 records involving 58 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lenvima by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 318 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 11505 records involving 4934 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Ibrance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORGOVYX as an associated drug or biological on 16373 records involving 6981 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Orgovyx by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Xtandi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $3,900.00 | 46.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $1,473.74 | 17.4% | 6 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $407.55 | 4.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $291.74 | 3.4% | 3 | 2025 |
| Blueprint Medicines Corporation | Unresolved — no canonical attribution shown | $218.39 | 2.6% | 2 | 2025 |
| Geron Corporation | Unresolved — no canonical attribution shown | $194.74 | 2.3% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $166.21 | 2.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $162.18 | 1.9% | 2 | 2025 |
| BeiGene USA, Inc. | Unresolved — no canonical attribution shown | $159.26 | 1.9% | 2 | 2025 |
| Genmab U.S., Inc. | Unresolved — no canonical attribution shown | $158.17 | 1.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $153.67 | 1.8% | 6 | 2025 |
| Kite Pharma, Inc. | Unresolved — no canonical attribution shown | $149.05 | 1.8% | 1 | 2025 |
| ADC THERAPEUTICS AMERICA, INC. | Unresolved — no canonical attribution shown | $138.15 | 1.6% | 2 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $116.05 | 1.4% | 1 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $96.90 | 1.1% | 7 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $88.22 | 1.0% | 4 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $84.45 | 1.0% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.32 | 0.7% | 3 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.56 | 0.6% | 3 | 2025 |
| Iovance Biotherapeutics, Inc. | Unresolved — no canonical attribution shown | $53.36 | 0.6% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $49.57 | 0.6% | 2 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $46.41 | 0.6% | 3 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $33.10 | 0.4% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.44 | 0.4% | 1 | 2025 |
| SERVIER PHARMACEUTICALS LLC | Unresolved — no canonical attribution shown | $29.28 | 0.3% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $28.51 | 0.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.11 | 0.3% | 1 | 2025 |
| Deciphera Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.98 | 0.3% | 1 | 2025 |
| Immunocore Limited | Unresolved — no canonical attribution shown | $21.72 | 0.3% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $19.85 | 0.2% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $16.89 | 0.2% | 1 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $16.39 | 0.2% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $15.27 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $5,200.00 | 2 |
| Food and Beverage | $3,262.23 | 71 |
| Education | $20.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| POTELIGEO Normalized: poteligeo |
Drug | KYOWA KIRIN, INC. | $3,900.00 | 1 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $1,417.86 | 2 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $407.55 | 3 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $234.62 | 2 | 2025 |
Source payment records
|
|||||
| RYTELO Normalized: rytelo |
Drug | Geron Corporation | $194.74 | 2 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc., BeiGene USA, Inc. | $186.64 | 5 | 2025 |
Source payment records
|
|||||
| Modeyso Normalized: modeyso |
Drug | JAZZ PHARMACEUTICALS INC. | $166.21 | 1 | 2025 |
Source payment records
|
|||||
| Epkinly Normalized: epkinly |
Drug | Genmab U.S., Inc. | $158.17 | 2 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | ARRAY BIOPHARMA INC, PFIZER INC. | $152.69 | 3 | 2025 |
Source payment records
|
|||||
| Yescarta Normalized: yescarta |
Drug | Kite Pharma, Inc. | $149.05 | 1 | 2025 |
Source payment records
|
|||||
| ZYNLONTA Normalized: zynlonta |
Drug | ADC THERAPEUTICS AMERICA, INC. | $138.15 | 2 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Drug | Blueprint Medicines Corporation | $117.72 | 1 | 2025 |
Source payment records
|
|||||
| Doptelet Normalized: doptelet |
Drug | SOBI, INC | $116.05 | 1 | 2025 |
Source payment records
|
|||||
| BLENREP Normalized: blenrep |
Biological | GlaxoSmithKline, LLC. | $111.92 | 1 | 2025 |
Source payment records
|
|||||
| TEVIMBRA Normalized: tevimbra |
Drug | BeOne Medicines USA, Inc., BeiGene USA, Inc. | $69.52 | 4 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $64.37 | 2 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $55.65 | 3 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $53.56 | 3 | 2025 |
Source payment records
|
|||||
| Amtagvi Normalized: amtagvi |
Drug | Iovance Biotherapeutics, Inc. | $53.36 | 2 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $49.57 | 2 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $46.41 | 3 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $46.41 | 3 | 2025 |
Source payment records
|
|||||
| OPDUALAG Normalized: opdualag |
Drug | E.R. Squibb & Sons, L.L.C. | $45.49 | 2 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $43.33 | 2 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $42.73 | 2 | 2025 |
Source payment records
|
|||||
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $41.12 | 2 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $33.65 | 1 | 2025 |
Source payment records
|
|||||
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $33.10 | 1 | 2025 |
Source payment records
|
|||||
| Somatuline Depot Normalized: somatuline depot |
Drug | Ipsen Biopharmaceuticals, Inc | $33.10 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $32.44 | 1 | 2025 |
Source payment records
|
|||||
| Tibsovo Normalized: tibsovo |
Drug | SERVIER PHARMACEUTICALS LLC | $29.28 | 2 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc. | $28.51 | 1 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc. | $28.51 | 1 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $27.18 | 1 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $25.11 | 1 | 2025 |
Source payment records
|
|||||
| QINLOCK Normalized: qinlock |
Drug | Deciphera Pharmaceuticals Inc. | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| TGCT Normalized: tgct |
Drug | Deciphera Pharmaceuticals Inc. | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC. | $24.75 | 2 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $24.75 | 2 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | PFIZER INC. | $24.75 | 2 | 2025 |
Source payment records
|
|||||
| KIMMTRAK Normalized: kimmtrak |
Drug | Immunocore Limited | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $19.85 | 1 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| ENJAYMO Normalized: enjaymo |
Drug | RECORDATI_RARE_DISEASES_INC. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $16.39 | 1 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $11.86 | 1 | 2025 |
Source payment records
|
|||||
| BOSULIF Normalized: bosulif |
Drug | PFIZER INC. | $11.86 | 1 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $11.86 | 1 | 2025 |
Source payment records
|
|||||
| LORBRENA Normalized: lorbrena |
Drug | ARRAY BIOPHARMA INC | $11.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BRUKINSA brukinsa |
2025 | Brukinsa | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| IBRANCE ibrance |
2025 | Ibrance | 2024 | 80 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| IMBRUVICA imbruvica |
2025 | Imbruvica | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JAKAFI jakafi |
2025 | Jakafi | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ORGOVYX orgovyx |
2025 | Orgovyx | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Somatuline Depot somatuline depot |
2025 | Somatuline Depot | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XTANDI xtandi |
2025 | Xtandi | 2024 | 96 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 15599 supporting records · 6881 recipient NPIs · example record 1201352838 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | IBRANCE open payments reported associated product |
CMS Open Payments — General Payments 54 supporting records · 52 recipient NPIs · example record 1228804288 |
Ibrance · 2024 Exact normalized brand match · 1 Part D row |
80 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | ORGOVYX open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 26 recipient NPIs · example record 1228888885 |
Orgovyx · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 98 supporting records · 88 recipient NPIs · example record 1228800820 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
96 | 17 |
| BeOne Medicines USA, Inc. Exact reporting entity; no affiliate inference |
2025 | BRUKINSA open payments reported associated product |
CMS Open Payments — General Payments 10251 supporting records · 4941 recipient NPIs · example record 1202883638 |
Brukinsa · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| BeiGene USA, Inc. Exact reporting entity; no affiliate inference |
2025 | BRUKINSA open payments reported associated product |
CMS Open Payments — General Payments 2084 supporting records · 1673 recipient NPIs · example record 1202877750 |
Brukinsa · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
318 | 99 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | SPRYCEL open payments reported associated product |
CMS Open Payments — General Payments 32 supporting records · 32 recipient NPIs · example record 1184390211 |
Sprycel · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | JAKAFI open payments reported associated product |
CMS Open Payments — General Payments 14854 supporting records · 6477 recipient NPIs · example record 1225959940 |
Jakafi · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Ipsen Biopharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | Somatuline Depot open payments reported associated product |
CMS Open Payments — General Payments 872 supporting records · 551 recipient NPIs · example record 1208821807 |
Somatuline Depot · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 33 recipient NPIs · example record 1174328453 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
215 | 49 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | LENVIMA open payments reported associated product |
CMS Open Payments — General Payments 66 supporting records · 58 recipient NPIs · example record 1237995778 |
Lenvima · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
318 | 99 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | IBRANCE open payments reported associated product |
CMS Open Payments — General Payments 11505 supporting records · 4934 recipient NPIs · example record 1228794164 |
Ibrance · 2024 Exact normalized brand match · 1 Part D row |
80 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ORGOVYX open payments reported associated product |
CMS Open Payments — General Payments 16373 supporting records · 6981 recipient NPIs · example record 1228794230 |
Orgovyx · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
96 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Anastrozole | Anastrozole | 318 | 125 |
| Eliquis | Apixaban | 318 | 99 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 242 | 70 |
| Xarelto | Rivaroxaban | 215 | 49 |
| Potassium Chloride | Potassium Chloride | 194 | 72 |
| Meloxicam | Meloxicam | 151 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 138 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 133 | 31 |
| Gabapentin | Gabapentin | 128 | 39 |
| Omeprazole | Omeprazole | 116 | 45 |
| Ondansetron Odt | Ondansetron | 114 | 67 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 113 | 77 |
| Dexamethasone | Dexamethasone | 104 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 100 | 17 |
| Xtandi | Enzalutamide | 96 | 17 |
| Ibrance | Palbociclib | 80 | suppressed |
| Prednisone | Prednisone | 70 | 34 |
| Methylprednisolone | Methylprednisolone | 66 | 49 |
| Hydrocortisone | Hydrocortisone | 63 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 62 | 38 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | 20 |
| Morphine Sulfate Er | Morphine Sulfate | 59 | 17 |
| Hydroxyurea | Hydroxyurea | 53 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 53 | 21 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 53 | 33 |
| Acyclovir | Acyclovir | 52 | 18 |
| Megestrol Acetate | Megestrol Acetate | 51 | 30 |
| Exemestane | Exemestane | 50 | 22 |
| Levofloxacin | Levofloxacin | 48 | 40 |
| Morphine Sulfate | Morphine Sulfate | 48 | 21 |
| Alprazolam | Alprazolam | 46 | 14 |
| Fentanyl | Fentanyl | 46 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 46 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 11 |
| Letrozole | Letrozole | 43 | 13 |
| Tramadol Hcl | Tramadol Hcl | 42 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 41 | 12 |
| Lenalidomide | Lenalidomide | 39 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 38 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | 11 |
| Orgovyx | Relugolix | 36 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 35 | 15 |
| Brukinsa | Zanubrutinib | 33 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 32 | 15 |
| Pomalyst | Pomalidomide | 32 | suppressed |
| Xtampza Er | Oxycodone Myristate | 32 | suppressed |
| Lorazepam | Lorazepam | 31 | 11 |
| Famotidine | Famotidine | 30 | 12 |
| Fluconazole | Fluconazole | 30 | 19 |
| Imatinib Mesylate | Imatinib Mesylate | 30 | suppressed |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Olanzapine | Olanzapine | 29 | 15 |
| Sodium Chloride | 0.9 % Sodium Chloride | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Jakafi | Ruxolitinib Phosphate | 27 | suppressed |
| Deferasirox | Deferasirox | 26 | suppressed |
| Magnesium Sulfate | Magnesium Sulfate | 26 | suppressed |
| Revlimid | Lenalidomide | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Udenyca Autoinjector | Pegfilgrastim-Cbqv | 26 | suppressed |
| Furosemide | Furosemide | 25 | 12 |
| Imbruvica | Ibrutinib | 25 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 25 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 24 | 11 |
| Nystatin | Nystatin | 22 | 19 |
| Oxycontin | Oxycodone Hcl | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 21 |
| Lonsurf | Trifluridine/Tipiracil Hcl | 21 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Somatuline Depot | Lanreotide Acetate | 19 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Diazepam | Diazepam | 17 | 13 |
| Nyvepria | Pegfilgrastim-Apgf | 17 | suppressed |
| Sprycel | Dasatinib | 17 | suppressed |
| Metformin Hcl | Metformin Hcl | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Lenvima | Lenvatinib Mesylate | 15 | suppressed |
| Lisinopril | Lisinopril | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Bexarotene | Bexarotene | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Xpovio | Selinexor | 13 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Neulasta | Pegfilgrastim | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Abiraterone Acetate | Abiraterone Acetate | 11 | suppressed |
| Demeclocycline Hcl | Demeclocycline Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Sucralfate | Sucralfate | 11 | suppressed |
| Zydelig | Idelalisib | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $8,482.23 · 74 records | KYOWA KIRIN, INC. | ADCETRIS, AYVAKIT, Amtagvi, BLENREP, BOSULIF, BRAFTOVI, BRUKINSA, DARZALEX, DATROWAY, Doptelet, ELREXFIO, ENJAYMO, Enhertu, Epkinly, FOTIVDA, Fabhalta, IBRANCE, IMBRUVICA, IMFINZI, JAKAFI, KEYTRUDA, KIMMTRAK, KISQALI, LIBTAYO, LORBRENA, MEKTOVI, Modeyso, OJJAARA, OPDIVO, OPDUALAG, ORGOVYX, Onivyde, PADCEV, POTELIGEO, PYRUKYND, QINLOCK, RYTELO, SARCLISA, SCEMBLIX, Somatuline Depot, TALZENNA, TECVAYLI, TEVIMBRA, TGCT, TUKYSA, Tibsovo, Trodelvy, XTANDI, Yescarta, ZYNLONTA | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Brukinsa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error